Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials

Article

Abstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: h

Palabras claves:

Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumab

Autores:

Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.

Fuentes:

scopus